Mulmit

Lantheus Holdings, Inc.Lantheus Holdings, Inc.

LNTH Nasdaq

Annual financials

PeriodRevenueOperating incomeNet incomeEPS
2025-12-311,541,609,000310,832,000233,559,0003.41
2024-12-311,533,910,000456,979,000312,442,0004.36
2023-12-311,296,429,000364,642,000326,661,0004.65
2022-12-31935,061,00036,195,00028,067,0000.4
2021-12-31425,208,000-60,825,000-71,279,000-1.06

Insider filings (Forms 3/4/5)

DateOwnerTitleShares
2026-09-04Lantheus Alpha Therapy, LLC167,149
2026-09-03Lantheus Alpha Therapy, LLC80,783
2026-09-02Lantheus Alpha Therapy, LLC42,129
2026-09-01Lantheus Holdings, Inc.35,769
2026-08-31Lantheus Holdings, Inc.78,145
2026-08-31Marshall Robert J. Jr.CFO and Treasurer721
2026-08-17Dinkelborg LudgerSee Remarks2,536
2026-08-17Brown KimberlyChief Accounting Officer463
2026-05-14Ber Gerard381
2026-05-14Heino Mary AnneExecutive Chair and CEO1,227
2026-05-14McHugh Julie4,137
2026-05-14Morrow Phuong Khanh4,137

8-K events

FiledItems
2026-09-21Other events
2026-08-06Results of operations · Financial statements and exhibits
2026-08-04Entry into a material agreement · Officer or director change · Financial statements and exhibits
2026-08-03Regulation FD disclosure · Other events · Financial statements and exhibits
2026-05-07Results of operations · Financial statements and exhibits
2026-05-01Material modification to rights of security holders · Officer or director change · Amendments to charter or bylaws · Submission of matters to a vote · Financial statements and exhibits
2026-02-26Results of operations · Financial statements and exhibits
2025-11-12Officer or director change
데이터를 불러오는 중입니다…Loading…

가격 차트Price chart

차트를 불러오는 중입니다…Loading chart…

In Vitro & In Vivo Diagnostic Substances — 같은 업종, 그리고 규모가 비슷한 기업In Vitro & In Vivo Diagnostic Substances — and other companies of a similar size

SEC가 같은 업종(In Vitro & In Vivo Diagnostic Substances)으로 분류한 기업이 먼저 오고, 그다음은 제출된 매출로 가까운 순입니다 — 가장 최근 연간 값이며, 연간 값이 없으면 최근 네 분기 합입니다. Companies the SEC assigns to the same industry (In Vitro & In Vivo Diagnostic Substances) come first, then the nearest by revenue as filed — the latest annual figure, or the last four quarters where no annual one is filed. 순서일 뿐 값이 싸거나 비싸다는 뜻이 아닙니다.Order only — it does not say a company is cheap or expensive.